BridgeMD
ADAPT: Treatment of Agitated behaviour in patients with Dementia non-responsive to guideline recommended interventions by Argued Personalised Treatment using an N-of-1 approach
EU CTIS ID: 2024-510601-29-00
What this study is testing
The main objective is to determine the effectiveness of psychotropic drugs not recommended by guidelines on agitated behaviour in patients with dementia.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Nursing home resident with dementia and agitated behaviour
- The treating physician has decided to prescribe quetiapine, olanzapine or lorazepam, in shared decision making with the patient and/or representative, independently of this trial.
You likely can't join if
- A life expectancy of <4 weeks, as estimated by the physician
- Inability to swallow the study capsules, assessed by the physician
- Actual alcohol and/or drug abuse
- The agitated behaviour is too unstable, as estimated by the physician
- Insufficient mastery of Dutch language, also applies to representatives if they provide informed consent
- The agitated behaviour is only present at night
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.